IMR Press / EJGO / Volume 21 / Issue 5 / pii/2000216

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Nuclear grading of endometrial cancer harbors heterogenous prognostic groups as detected by proliferation activity

Show Less
1 Department of Obstetrics & Gynaecology, University of Kiel, Germany
2 Oncological Center, Warsaw, Poland
Eur. J. Gynaecol. Oncol. 2000, 21(5), 475–478;
Published: 10 October 2000

Objective: Nuclear grading, in addition to the histopathological result of every tumor, is responsible for consecutive treatment designs. Ki-S5 is the monoclonal antibody against a formalin-resistant epitope of the Ki-67 antigen and can be determined in paraf­fin-embedded samples. The aim of the study was a comparative analysis of the nuclear grading of endometrial cancer and the pro­liferation marker Ki-S5. Methods: In 126 specimens of endometrial cancer the proliferation activity of the monoclonal antibody Ki-S5 was determined (streptavidin-biotin-complex method) in correlation to nuclear grading. In the group of grade 2, stages lb and le andenocarcinomas, proliferation rates were compared to recurrence rates. Results: Divergent proliferation rates resulted. Adenoacanthomas showed a relatively low proliferation rate (<28%). For the ande­nosquamous carcinomas the proliferation rate ranged between 28-43%. The largest group of adenocarcinomas showed proliferation rates from 5-74%. A clear dependency between increasing proliferation rates and decreasing differentiation (nuclear grading 2-3) was observed. In the small group of patients with andenocarcinomas, nuclear grading G2 stages Ib and Ic, 38 suffered no recurrence after 6-10 years. However, the six patients with proliferation rates of over 35% all suffered a recurrence. Conclusions: The results emphasize the need to differentiate G2 tumors, depending on their proliferation rate, into low risk (KiS5<35%) and high risk cases (Ki-S5>35%).

Endometrial cancer
Nuclear grading
Ki-S5 proliferation activity
Back to top